The new total-body PET scanner has been introduced at the Turku PET Centre. This new generation of medical imaging devices offers novel methods for studying diseases that affect the entire body, not only a single organ. Such diseases include diabetes, coronary artery disease, and multiple sclerosis. For the patient, being able to use the new device means a lower amount of radiation and a shorter scanning time.
Professor and Chief Physician, InFLAMES group leader Pirjo Nuutila is receiving the 2022 Novo Nordisk Foundation Lecture prize for her contribution to research on metabolic diseases such as overweight and diabetes.
The new study from Turku Bioscience provides new insights into how genetic variation associated with immune mediated diseases can influence T-cell function and regulation of immune response. The study was published in Nucleic Acid Research.
The InFLAMES and INVEST Flagships of the University of Turku offer grants for Ukrainian researchers who are unable to continue their work in Ukraine due to the Russian invasion.
InFLAMES (Innovation Ecosystem based on the Immune System) is a Finnish research flagship that aims at identifying novel drug targets using the most modern technological platforms and finding novel diagnostic tools to identify the patients benefitting from personalised therapies.
This year BioCity Symposium is arranged on-site in Mauno Conference Centre, BioCity, together with InFLAMES Research Flagship 25–26 August 2022, with the title Solution is in Immunity. Registration is now open until 11 August 2022.
Children who develop type 1 diabetes show epigenetic changes in the cells of their immune system already before the antibodies of the disease are detected in their blood. The findings of two new studies offer new opportunities to identify the children with the genetic risk for developing diabetes very early on.
Minister of Family Affairs and Social Services Krista Kiuru signed an agreement on the establishment of the national Drug Development Centre (Kansallinen lääkekehityskeskus Oy) on Friday, 4 February 2022. The establishment of the national Drug Development Centre in Turku will promote competitive drug development, and it will serve the researchers in the whole country, for example in universities, research centres, and hospitals.
InFLAMES (Innovation Ecosystem based on the Immune System) is a Finnish research flagship that aims at identifying novel drug targets using the most modern technological platforms and finding novel diagnostic tools to identify the patients benefitting from personalised therapies.
The Academy of Finland has granted a continued funding of over 9 million euros to the Inequalities, Interventions and New Welfare State Flagship INVEST. The funding period extends until 2026. The international review panel which completed a mid-term review of the Flagship found its activities excellent and very successful while also considering its plans for the future promising.